Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Review Article

Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC)

John Nolan, Agatha Nadya Lianto, Audrey Rachel Wijaya, Cokorda Agung Wahyu Purnamasidhi.

Sepsis-induced coagulopathy (SIC) is a unique and urgent condition characterized by coagulation activation, overexpression of fibrinolysis, and high risk of organ dysfunction following sepsis. SIC is one of the complications of sepsis that is leading to high mortality rate. Due to the fact that there is no exact effective therapeutic agents specifically designed for SIC, new modalities are needed regarding the potential effect to suppress the mortality rate. Antithrombin (AT) and recombinant thrombomodulin (rhTM) are drugs which can promote anticoagulant activity. These natural anticoagulants work complementary to each other so that may suppress damage-associated molecular patterns (DAMPs) which is a process that may trigger endogenous molecule worsening the SIC. AT and rhTM have similar clinical effect on the other hand this AT-rhTM combination works on different sites and targets in the process. AT-rhTM combination may also suppress leukocyte adhesion and the elevation of circulating levels of nucleosome which leading to cell death event. Unfortunately, AT-rhTM combination costs extremely expensive. This article is done by searching journals with keywords “antithrombin”, “thrombomodulin”, and “sepsis induced coagulopathy” on the search engines. From 55 journals that were reviewed, 46 were found suitable as reference for this paper. AT-rhTM agent on SIC may reduce the mortality rate following some mechanisms. Further researches are required to identify the efficacy and effectivity of the AT-rhTM combination in treating patients with SIC

Key words: AT-rhTM combination, mortality, SIC

Full-text options

Full-text Article

American Journal of Diagnostic Imaging


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.